Serzonil, Nefadar, and Rulivan. In April 2004, BMS announced that it was going to discontinue the sale of Serzone in the United States in June 2004 and said that this was due to declining sales. By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada. As of 2012, generic nefazodone was still available in the United States. In August 2020, Teva Pharmaceuticals placed nefazodone in shortage due to a shortage of a raw ingredient. On December 20, 2021, nefazodone was again made available in all strengths. Society and culture Generic names Nefazodone is the generic name of the drug and its and , while néfazodone is its and nefazodone hydrochloride is its and . Brand names Nefazodone has been marketed under a number of brand names including Dutonin (, , , ), Menfazona (), Nefadar (, , , ), Nefazodone BMS (), Nefazodone Hydrochloride Teva (), Reseril (), Rulivan (), and Serzone (, , ). Research Nefazodone was under development for the treatment of panic disorder, and reached phase 3 clinical trials for this indication, but development was discontinued in 2004. The use of nefazodone to prevent migraine has been studied, due to its antagonism of the serotonin 5-HT2A and 5-HT2C receptors. References External links Alpha-1 blockers Alpha-2 blockers Antidepressants Anxiolytics 5-HT1A agonists 5-HT2A antagonists 5-HT2C antagonists CYP3A4 inhibitors H1 receptor antagonists Hepatotoxins Phenol ethers 2-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-1,2,4-triazol-3-ones Serotonin–norepinephrine–dopamine reuptake inhibitors Ureas Withdrawn drugs